Overview

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Status:
Completed

Trial end date:
2018-08-15

Target enrollment:

Participant gender:

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus

Phase:

Phase 3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Liraglutide